Orchid Pharma Limited has informed the Exchange about the execution of Deed of Hypothecation in favour of HDFC Bank Limited
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma has secured new credit facilities of Rs. 142.5 crore (Rs. 1,425 million) from HDFC Bank by executing a Deed of Hypothecation on July 17, 2025. The funding is specifically earmarked for setting up the company's Cefiderocol Project. A Deed of Hypothecation means the company has pledged its movable assets (such as inventory or receivables) as collateral to secure this loan. Cefiderocol is a specialised antibiotic used to treat serious drug-resistant bacterial infections, and this project appears to be a major capacity expansion or manufacturing initiative for this product.
This is a fresh borrowing that will increase the company's debt levels by Rs. 142.5 crore, but it is tied to a specific growth project (Cefiderocol) rather than general working capital. Shareholders should view this as a funded expansion plan, though it will raise interest costs and add leverage in the near term. The stock may react based on how the market views the Cefiderocol project's revenue potential.